BriaCell Therapeutics Corp. BCT.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · briacell.com
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted cellular immunotherapies for cancer treatment. Its lead program, Bria-IMT™, is in a pivotal Phase 3 clinical trial for metastatic breast cancer, while Bria-OTS™ is a personalized off-the-shelf immunotherapy designed to match patients' HLA types. The company also holds a license from the University of Maryland to develop soluble CD80 as a biologic cancer treatment.
Key ratios
ReturnOnAssets TTM -0.91
ReturnOnAssets 2025 -1.24
ReturnOnAssets 2024 -1.26
ReturnOnAssets 2023 -0.42
ReturnOnEquity TTM -1.75
ReturnOnEquity 2025 -3.63
ReturnOnEquity 2023 -6.2
Recent news
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
2026-07-16 · GlobeNewswire
BriaCell Therapeutics Announces Closing of Offering
2026-06-02 · GlobeNewswire
BriaCell Presents Positive Clinical Data at ASCO 2026
2026-06-01 · BioSpace